The medication is commonly used to help manage symptoms related to the emetic response in challenging clinical contexts. It is used in situations involving certain distressing symptoms, applied across domains where additional symptomatic support is needed.

This use is relevant for managing symptoms that interfere with daily comfort in conditions marked by heightened symptoms, specifically Chemotherapy-Induced Nausea and Vomiting (CINV), including the acute and delayed phases, and for Postoperative Nausea and Vomiting (PONV) in adults. It is applied in clinical settings involving highly or moderately emetogenic regimens (HEC/MEC) to help address symptoms that create noticeable physiological strain. The medication helps maintain a sense of stability when symptoms are more noticeable. This supportive action contributes to easing the overall symptom load.

---

Quick Fact: Relief for Acute and Delayed Emesis
Primary Use: Prophylactic management of severe nausea and vomiting in high-risk patients.
Target Contexts: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), and Postoperative Nausea and Vomiting (PONV).
Key Benefit: Contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

Regulatory References

1. Aprepitant MedlinePlus Drug Information

Who Can and Cannot Use Эменд (Aprepitant)

The population eligibility for Эменд is strictly defined by regulatory authorities based on contraindications, age, and physiological status.

Absolute Prohibitions (Contraindications)

Эменд is contraindicated and must not be used in patients with known hypersensitivity to Aprepitant or its components. It is also absolutely prohibited for patients concurrently receiving the medicines pimozide, terfenadine, astemizole, or cisapride due to the potential for serious or life-threatening drug-drug interactions.

Eligibility by Age and Condition

Population Group	Eligibility Status	Specific Restriction
Adults	Eligible (CINV and PONV prophylaxis).	No dosage adjustment needed for older adults.
Pediatric (CINV)	Eligible for CINV prophylaxis.	Approved for patients 6 months of age and older.
Pediatric (PONV)	Not established.	Safety/efficacy for PONV prophylaxis is not established below 18 years of age.
Hepatic Impairment	Conditional use.	Caution is advised in moderate to severe impairment.
Renal Impairment	Eligible.	No dose adjustment is required.
Pregnancy/Lactation	Not recommended.	Use is not recommended during pregnancy or breastfeeding.

Interactions with other medicines and products

Эменд (aprepitant) is documented to affect, and be affected by, other substances through its interaction with the cytochrome P450 enzyme systems, primarily acting as a moderate inhibitor of CYP3A4 and an inducer of CYP2C9 and glucuronidation.

Contraindicated Combinations:

Regulatory authorities strictly prohibit co-administration with medicines that are highly metabolized by CYP3A4 and have narrow therapeutic indexes, due to the potential for significantly increased plasma concentrations and serious reactions. This includes pimozide, terfenadine, astemizole, and cisapride.

Interactions Requiring Caution or Adjustment:

Due to its effect on CYP3A4, Эменд may increase the exposure of many co-administered drugs. A 50% dose reduction of dexamethasone is required when used concomitantly. Close clinical monitoring is necessary for co-administration with other narrow therapeutic index CYP3A4 substrates, such as alfentanil, cyclosporine, tacrolimus, sirolimus, everolimus, quinidine, and ergot alkaloid derivatives (e.g., ergotamine).

As a CYP2C9 inducer, Эменд can decrease plasma concentrations of medicines like warfarin. Patients receiving warfarin require intensive monitoring of the International Normalized Ratio (INR), particularly in the two weeks following the start of the Эменд regimen.

Hormonal Contraceptives:

Due to enzyme induction, the efficacy of hormonal contraceptives may be reduced during and for 28 days following the last dose of the Эменд regimen. Patients using these contraceptives must be advised to use alternative, non-hormonal, barrier methods.

How Эменд Works: The Pharmacological Mechanism

Targeted Blockade of the NK1 Receptor System

The active compound, Aprepitant, is a highly selective antagonist of the Neurokinin 1 ( NK1) receptor. This mechanism operates by tightly binding to the receptor, thereby preventing the natural signaling molecule, Substance P, from activating the pathway. This targeted molecular action is crucial for the modulation of the neural activity that initiates the central reflex.

---

Attenuating the Central Emetic Cascade

The drug is designed to be brain penetrant, achieving high and sustained receptor occupancy primarily within the brainstem's vomiting centers (Area Postrema and NTS). By inhibiting signal transduction in these nuclei, the drug attenuates the central pattern generator's output, thus restricting the coordinated motor and autonomic functions of the reflex arc. The pro-drug, Fosaprepitant, rapidly converts to Aprepitant to ensure rapid achievement of this high central receptor occupancy.

---

Mechanism of Multi-Pathway Complementarity

Aprepitant’s NK1 blockade is mechanistically distinct from other antiemetic pathways, such as those governed by serotonin ( 5-HT3 receptors) or humoral factors (corticosteroids). This complementary action facilitates simultaneous engagement of multiple emetic pathways, resulting in a broad physiological suppression by targeting multiple independent signaling pathways.

How to use Эменд (Aprepitant/Fosaprepitant) — Administration Guidelines

This medication is administered only as part of a fixed, multi-drug antiemetic regimen and must adhere strictly to the established dose, route, and timing.

Administration Scope

Attribute	Instruction
Route of Administration	Oral (capsules or suspension) or Intravenous (IV) infusion (fosaprepitant)
Timing in Relation to Meals	May be taken with or without food
Special Procedural Condition	Must be administered concurrently with a corticosteroid and a 5-HT3 antagonist, with the corticosteroid dose often reduced by 50% due to co-administration rules

Dosing and Schedule for Prevention of Nausea and Vomiting

Patient Population	Day 1	Day 2 & Day 3
Adults (Oral Capsules)	125 mg orally 1 hour prior to chemotherapy.	80 mg orally once daily in the morning (or 1 hour prior to chemotherapy if given).
Adults (IV Infusion)	150 mg intravenously over 20-30 minutes, completing the infusion approximately 30 minutes prior to chemotherapy.	No further dose administered (single-day regimen).
Adults (Postoperative)	40 mg orally as a single dose within 3 hours prior to induction of anesthesia.	No further dose administered.
Pediatrics (12+ years)	125 mg orally 1 hour prior to chemotherapy.	80 mg orally once daily in the morning (or 1 hour prior to chemotherapy if given).
Pediatrics (6 months to <12 years)	Weight-based dose of oral suspension administered 1 hour prior to chemotherapy.	Weight-based dose of oral suspension once daily in the morning (or 1 hour prior to chemotherapy if given).

Oral capsules must be swallowed whole. The liquid oral suspension must be prepared by a healthcare professional and is reserved for pediatric patients or those unable to swallow capsules. Chronic continuous administration is not recommended.

Research evidence / Overview of studies for Эменд

---

Evidence for use in preventing chemotherapy-induced nausea and vomiting (CINV)

Research explored the use of Эменд in settings related to physical discomfort, specifically the nausea and vomiting that can follow certain cancer treatments. These are conditions characterized by fluctuating or episodic manifestations. Studies examined what was observed when Эменд was evaluated in studies exploring how symptoms may be reduced or avoided during chemotherapy. These studies were conducted during periods of increased symptom activity to see how often patients experienced acute episodes where symptoms become more noticeable.

The findings describe patterns observed in these studies, which generally relate to outcomes describing episodic changes in nausea and vomiting. Research so far indicates that the studies collected data on the severity and frequency of these symptoms when Эменд was included in specific treatment regimens. However, evidence quality varies across studies, and for certain types of chemotherapy, findings were mixed. Subgroup findings remain uncertain.

---

Evidence for use in preventing post-operative nausea and vomiting (PONV)

Эменд was also evaluated in research exploring short-term symptom changes in patients in the immediate post-operative period. These studies monitored outcomes related to systemic or functional imbalance that can occur right after an operation. The data show patterns related to outcomes reflecting daily functioning or activity level immediately following surgery, which was studied in settings where symptoms were expected. Comparative evidence is lacking when looking at how Эменд was studied relative to all other approaches studied in this research context.

---

Long-term studies and follow-up

Research examined what was observed over defined time intervals, focusing on the changes in symptoms over time after initial evaluation. What happens over long time intervals is not fully established. Follow-up durations were limited in most of the initial trials. There is limited information for long-term outcomes, and research is ongoing to further understand the durability of the observed patterns.

---

Evidence in special populations

Эменд was observed in some studies that included individuals in special populations, such as older adults and children. Data for certain groups remain insufficient, and research is ongoing concerning these specific populations. Evidence is limited for populations such as pregnant women or individuals with significant liver or kidney conditions. Findings describe group patterns, not personal outcomes, for these specialized populations.

---

What is still uncertain about Эменд

Research highlights what is known—and what is still uncertain—about Эменд. The main research limitations include that follow-up durations were often limited, and sample sizes were sometimes modest, especially in studies concerning special populations. Data are still emerging, and research provides context but not individual predictions. The certainty of some findings remains low.

Key Studies & References

1. Aprepitant for postoperative nausea and vomiting: A systematic review and meta-analysis (Singh et al., 2016)
2. Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Refractory or High-Risk Patients (CADTH Rapid Review, 2022) - Evidence Limitations
3. Long-Term Daily Administration of Aprepitant for the Management of Intractable Nausea and Vomiting in Children With Life-Limiting Illness (Patel et al., 2021) - Pediatric/Off-label context

Common questions about Эменд (FAQ)

Q: Can I drink alcohol while taking this medicine?

A: Official product information advises limiting or avoiding alcohol consumption while using this medication. Alcohol can increase nervous system side effects such as dizziness, drowsiness, and difficulty concentrating, which are also common effects of the medicine itself. Combining them may potentially make these effects worse.

Q: Can I take this medication if I am pregnant or planning to be?

A: Regulatory documents state that this medicine is generally not recommended during pregnancy because it may pose a risk of harm to the fetus. Women who are able to become pregnant should use effective birth control while taking this medicine. Concerns regarding pregnancy should be addressed with a healthcare provider.

Q: Does this medicine make you tired or sleepy?

A: Yes, dizziness and somnolence, which means sleepiness or drowsiness, are listed in official product labeling as very common side effects of this medicine. Awareness of this potential effect is relevant, particularly when starting treatment.

Q: What should I do if I forget a dose?

A: Product information generally states that if a dose is missed by a few hours, it may be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, regulatory labeling advises skipping the missed capsule and continuing with the regular schedule. Regulatory labeling cautions against taking two doses simultaneously to compensate for a missed dose.

Q: Does this medicine affect my ability to drive?

A: Yes, because this medicine can cause dizziness, drowsiness, and reduced alertness, an individual's ability to drive or operate complex machinery may be affected. It is advised to understand how the medication affects an individual before performing these tasks.

Q: Is it safe to breastfeed while taking this medicine?

A: Official product information suggests that breastfeeding is not recommended while taking this medicine. This is because the active substance can pass into breast milk, and the potential effects on a nursing infant are not known.

Q: What is the recommended storage temperature for the capsules?

A: To maintain the quality of the medication, the capsules should typically be stored in a cool, dry place. The official storage advice often recommends keeping the medicine below a specific temperature, such as 30°C, and away from direct light and moisture. It should not be refrigerated.

Q: What are the risks of suddenly stopping this medication?

A: Official labeling advises against stopping this medication suddenly without consulting a healthcare provider. Abrupt discontinuation may lead to withdrawal symptoms. These symptoms can include headaches, seizures, nausea, diarrhea, and difficulty sleeping.

Q: Can this medication cause weight gain?

A: Yes, weight gain is listed in official regulatory documents as a commonly reported side effect among people taking this medication.

Q: Is it safe for a child who is 10 years old?

A: The approved uses for this medicine, such as for nerve pain and fibromyalgia, are generally restricted to adults 18 years of age and older. Official regulatory bodies have not established safety and effectiveness for its use in children under 18 for most of the primary conditions it is indicated for.

How to Store and Dispose of Emend (Aprepitant/Fosaprepitant)

Official storage and disposal instructions are dictated by the specific product form to maintain stability and integrity.

Storage Requirements

Product Form	Temperature and Container Rules
Emend Capsules	Store at room temperature (20 C to 25 C), protected from moisture, and kept in the original container, tightly closed.
Prepared Oral Suspension	Must be refrigerated (2 C to 8 C) and discarded after 72 hours, or discarded if kept at room temperature for over 3 hours.
Reconstituted IV Solution	Stable for 24 hours at ambient room temperature (at or below 25 C).

All forms must be stored out of the sight and reach of children.

Disposal

Any unused portion of the prepared suspension or intravenous solution must be discarded. The active substance should not be released into the environment, such as surface water or the sanitary sewer system, and disposal should follow local pharmaceutical waste regulations.